# Pharmascience

> Pharmascience is a VC fund backing Biotechnology and Pharmaceutical. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 6
- Last investment: Nov 2017
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/pharmascience
- X (Twitter): https://twitter.com/_pharmascience_
- Website: http://www.pharmascience.com/
- Facebook: https://www.facebook.com/Pharmascience/

Pharmascience is a leading manufacturer of generic drugs in Canada.

## Contacts

5 contacts available for Pharmascience. Shizune tracks 1 team members at Pharmascience. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pharmascience?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Pharmaceutical | 4 | 67% |
| Health Care | 2 | 33% |
| Medical | 1 | 17% |
| Life Science | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |
| Private Equity | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Canada | 1 | 17% |
| Israel | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Morris Goodman | Founder | 0 | https://shizune.co/investors/profile/morris-goodman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RDD Pharma | RDD is focused on developing targeted therapeutics and delivery systems for treating diseases of the anorectal region and lower gastrointestinal tract. In order to treat diseases in this challenging area, drugs require special formulation and delivery/application techniques to address wide variations in anatomy and physiology. | $9.5M | Series B | Nov 16, 2017 |  |
| Edesa Biotech | Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatorymolecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies. | $7M | Series A | Sep 20, 2017 |  |
| Stellar Biotechnologies | Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function. KLH can also be used inimmunotoxicology studies for monitoring the immunomodulatory effects of drug candidates. | $7M | Post-IPO Equity | Sep 20, 2017 |  |
| Pharmaceutics International | Pii is a science-driven contract development and manufacturing company providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Pii’s vision is to be the benchmark in pharmaceutical product development outsourcing. They strive to do this with their mix of broad scientific capabilities, seasonedtalent, attentive customer service and an exceptional quality record. By providing extensive technical capabilities and a high level of customer service, Pii continues to grow with new and repeat business. This has resulted in a balanced client base of major multinational and virtual pharmaceutical companies located across the globe. | $93M | Private Equity | Sep 06, 2016 |  |
| Pharmaceutics International | Pii is a science-driven contract development and manufacturing company providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Pii’s vision is to be the benchmark in pharmaceutical product development outsourcing. They strive to do this with their mix of broad scientific capabilities, seasonedtalent, attentive customer service and an exceptional quality record. By providing extensive technical capabilities and a high level of customer service, Pii continues to grow with new and repeat business. This has resulted in a balanced client base of major multinational and virtual pharmaceutical companies located across the globe. | $93M | Private Equity | Sep 06, 2016 |  |
| BionPharma | BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships. It is licensed to do business in the United States and is accomplished in the areas of product development, regulatory affairs, quality management, sales and distribution, and supply chain management. Today, Bionpharma is one of thelargest suppliers of soft gel capsules in the US market with a strong presence in both the prescription and over-the-counter markets.Launched in 2014, BionPharma was founded by a team of executives and professionals with years of cumulative experience in the generics industry. It is based in Princeton, New Jersey, and with offices in Raleigh, North Carolina. | $30.7M |  | Feb 09, 2015 |  |

6 of 6 investments shown.

## Co-investors
- [Signet Healthcare Partners](https://shizune.co/investors/profile/signet-healthcare-partners) — VC Fund, 3 deals together
- [Athyrium Capital Management LP](https://shizune.co/investors/profile/athyrium-capital-management) — VC Fund, 2 deals together
- [Hildred Capital Partners](https://shizune.co/investors/profile/hildred-capital-partners) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [Capital Point](https://shizune.co/investors/profile/capital-point) — VC Fund, 1 deal together
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Pharmascience invest in?

Pharmascience invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pharmascience?

Public channels for Pharmascience include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pharmascience?

The team at Pharmascience includes Morris Goodman (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co